TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24686184

Group type: EXPERIMENTAL
Intervention: tango+tDCS
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 1

Group type: COMPARATOR
Intervention: sham
Number of subjects: 1
Study: 23110471

Group type: EXPERIMENTAL
Intervention: Olmesartan 40 mg, Amlodipine 10 mg, Hydrochlorothiazide 25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olmesartan 40 mg, Amlodipine 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olmesartan 40 mg, Hydrochlorothiazide 25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine 10 mg, Hydrochlorothiazide 25 mg
Number of subjects: 0
Study: 20207345

Group type: EXPERIMENTAL
Intervention: Psychoeducation regarding thought-action fusion (TAF)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Psychoeducation regarding thoughts in general
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 139
Study: 18926223

Group type: EXPERIMENTAL
Intervention: Fibrin glue (Tisseel) used as a sealant after hypospadias surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: No sealant used (Control group)
Number of subjects: 120
Study: 15830221

Group type: EXPERIMENTAL
Intervention: 0.5 mg alprazolam
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.0 mg alprazolam
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 2.0 mg alprazolam
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12613304

Group type: EXPERIMENTAL
Intervention: NRC + Prime & Bond + Dyract Seal (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional phosphoric acid + Helioseal (Group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional phosphoric acid and rinse (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NRC + Helioseal (Group D)
Number of subjects: 60
Study: 27093744

Group type: EXPERIMENTAL
Intervention: Captopril 12.50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril 25.00 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril 6.25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7489623

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced helical CT studies
Number of subjects: 300
Study: 2317417

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.1-0.6%)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Midazolam (0.01-0.2 mg kg-1 h-1)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 46

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 46
Study: 547369

Group type: EXPERIMENTAL
Intervention: Lung scans interpreted as high probability for pulmonary emboli
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lung scans interpreted as low probability for pulmonary emboli
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Radionuclide scans interpreted as nondiagnostic
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pulmonary arteriography
Number of subjects: 30
Study: 31623042

Group type: EXPERIMENTAL
Intervention: Rhodiola rosea + non-invasive ventilator
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rhodiola rosea
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-invasive ventilator
Number of subjects: 90
Study: 28215471

Group type: EXPERIMENTAL
Intervention: RP5063 15mg
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: RP5063 30mg
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: RP5063 50mg
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: RP5063 (all doses combined)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: RP5063
Number of subjects: 234
Study: 26114240

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 441 mg
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 882 mg
Number of subjects: 623

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 623
Study: 23090718

Group type: EXPERIMENTAL
Intervention: Positive mood induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral mood induction
Number of subjects: 0
Study: 21883353

Group type: EXPERIMENTAL
Intervention: Tobramycin once daily
Number of subjects: 61

Group type: COMPARATOR
Intervention: Tobramycin three times daily
Number of subjects: 61
Study: 19711610

Group type: EXPERIMENTAL
Intervention: Rotation-oscillation power toothbrush
Number of subjects: 171

Group type: COMPARATOR
Intervention: Sonic power toothbrush
Number of subjects: 171
Study: 17309949

Group type: EXPERIMENTAL
Intervention: Statin therapy (291 patients in parallel group trials)
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Statin therapy (in crossover trials, 265 patients)
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 828
Study: 15152059

Group type: EXPERIMENTAL
Intervention: Cardiac-resynchronization therapy with a pacemaker
Number of subjects: 1520

Group type: EXPERIMENTAL
Intervention: Cardiac-resynchronization therapy with a pacemaker-defibrillator
Number of subjects: 1520

Group type: COMPARATOR
Intervention: Optimal pharmacologic therapy alone
Number of subjects: 1520
Study: 11382723

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa (rVIIa) 90 microgram/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nematode anticoagulant protein c2 3.5 microgram/kg
Number of subjects: 0
Study: 9289367

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8489989

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine (BUPI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl subcutaneous infusion (F-SC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl plus bupivacaine infusion (F-PLX)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single block (PLX)
Number of subjects: 40
Study: 3114663

Group type: EXPERIMENTAL
Intervention: 240 mg of crystalline melatonin (aMT) administered orally
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2802036

Group type: EXPERIMENTAL
Intervention: Antibiotic mouthwash
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 12
Study: 31046809

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 7355

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 7355
Study: 28455091

Group type: EXPERIMENTAL
Intervention: Nurse Practitioners (NPs)
Number of subjects: 770

Group type: COMPARATOR
Intervention: Attending Physicians
Number of subjects: 770
Study: 26029921

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 243

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control
Number of subjects: 243
Study: 23210544

Group type: EXPERIMENTAL
Intervention: Office bleaching method
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Home bleaching method
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no bleaching)
Number of subjects: 45
Study: 21810106

Group type: EXPERIMENTAL
Intervention: 16 sessions of psychotherapy combined with pharmacotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: 8 sessions of psychotherapy combined with pharmacotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both 8 and 16 sessions of psychotherapy combined with pharmacotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients in remission
Number of subjects: 0
Study: 19537522

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg tablet (test preparation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Escitalopram 10 mg tablet (reference preparation)
Number of subjects: 20
Study: 16702182

Group type: EXPERIMENTAL
Intervention: R-ICE (ifosfamide, carboplatin, etoposide combined with rituximab)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: R-DHAP (dexamethasone, ara‐C and cisplatin combined with rituximab)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance treatment (375 mg/m2, one injection every 2 months for six times)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Observation (control group for maintenance treatment)
Number of subjects: 400
Study: 15272688

Group type: EXPERIMENTAL
Intervention: QWIP (quantum well infrared photodetector) imaging technique
Number of subjects: 6

Group type: COMPARATOR
Intervention: NIRS and LDF measurements
Number of subjects: 6
Study: 11511335

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 19

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both positions
Number of subjects: 19
Study: 9024711

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Anastrozole 10 mg
Number of subjects: 386

Group type: COMPARATOR
Intervention: Megestrol acetate
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 386
Study: 8342318

Group type: EXPERIMENTAL
Intervention: 1991‐1992 trivalent split influenza vaccine (A/Singapore/6/86 (H1N1), A/Beijing/353/89 (H3N2), B/Yamagata/16/88)
Number of subjects: 296

Group type: COMPARATOR
Intervention: H3N2 and B components
Number of subjects: 296
Study: 3569766

Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg, q.i.d. for 4 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31752637

Group type: EXPERIMENTAL
Intervention: Evacetrapib
Number of subjects: 1624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1624
Study: 27986357

Group type: EXPERIMENTAL
Intervention: Less dilated left ventricles (EDVI < 90 mL/m2)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Reduction in baseline dyssynchrony
Number of subjects: 260

Group type: COMPARATOR
Intervention: Severely dilated left ventricles (EDVI ≥ 90 mL/m2)
Number of subjects: 260
Study: 25102205

Group type: EXPERIMENTAL
Intervention: Norepinephrine/low volume group (2 μg/kg per hour norepinephrine + 1 ml/kg per hour initially and 3 ml/kg per hour crystalloid infusion after cystectomy)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard crystalloid infusion group (6 ml/kg per hour throughout surgery)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Norepinephrine/low volume group
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard crystalloid infusion group
Number of subjects: 93
Study: 23798626

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Expressed Breast Milk (EBM)
Number of subjects: 65
Study: 21415720

Group type: EXPERIMENTAL
Intervention: Real TMS stimulation at 1 Hz 80% resting motor threshold (rMT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Real TMS stimulation at 1 Hz 100% rMT
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Real TMS stimulation at 10 Hz 80% rMT
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Real TMS stimulation at 10 Hz 100% rMT
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Real TMS stimulation at 50 Hz triplets at 90% of active motor threshold (intermittent theta-burst)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 65
Study: 18971883

Group type: EXPERIMENTAL
Intervention: Piracetam (12 g at the beginning of the operation)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 16782917

Group type: EXPERIMENTAL
Intervention: Trastuzumab, paclitaxel, and carboplatin (TPC)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Trastuzumab and paclitaxel (TP)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Trastuzumab, paclitaxel, and carboplatin (TPC) in HER‐2 3+ patients
Number of subjects: 196

Group type: COMPARATOR
Intervention: Trastuzumab and paclitaxel (TP) in HER‐2 3+ patients
Number of subjects: 196
Study: 12707726

Group type: EXPERIMENTAL
Intervention: FLAG-IDA (fludarabine 30 mg/m(2), AraC 2 g/m(2) for 5 days, idarubicin 10 mg/m(2) for 3 days, G‐CSF 5 micro g/kg from day +6 until neutrophil recovery)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: FLAG-IDA
Number of subjects: 46
Study: 10522638

Group type: EXPERIMENTAL
Intervention: Ballet dancers
Number of subjects: 126

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 126
Study: 7494233

Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy via two-vessel treatment
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy via one-vessel treatment
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy via middle-cerebral artery treatment
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group in the BTCG phase III trial of intra-arterial chemotherapy
Number of subjects: 102
Study: 1788749

Group type: EXPERIMENTAL
Intervention: i.v. infusion of 40 micrograms PGE1 in 125 ml saline over 60 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: i.a. infusion of 10 micrograms PGE1 in 25 ml saline over 30 min
Number of subjects: 20
Study: 6756705

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Angiotensin II infusion (5, 10, and 20 ng/kg/min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control infusions (placebo)
Number of subjects: 6
Study: 31738113

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation
Number of subjects: 386

Group type: COMPARATOR
Intervention: OnabotulinumtoxinA
Number of subjects: 386
Study: 29482649

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus 5-fluorouracil (TF) concurrent with radiotherapy (5-fluorouracil 300 mg/m2 continuous infusion for 96 h plus paclitaxel 50 mg/m2 on day 1 for 5 weeks) followed by consolidation chemotherapy (5-fluorouracil 1800 mg/m2 continuous infusion for 72 h plus paclitaxel 175 mg/m2 on day 1 for 2 cycles)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Cisplatin plus 5-fluorouracil (PF) concurrent with radiotherapy (cisplatin 25 mg/m2/d on days 1-3 plus 5-fluorouracil 1800 mg/m2 continuous infusion for 72 h for 2 cycles) followed by consolidation chemotherapy for 2 cycles
Number of subjects: 436
Study: 26992007

Group type: EXPERIMENTAL
Intervention: Provisional phase with soft tissue conditioning using the 'dynamic compression technique' (Group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Without a provisional (Group 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Provisional phase with soft tissue conditioning (Group 1)
Number of subjects: 20
Study: 23901798

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control
Number of subjects: 133
Study: 22374842

Group type: EXPERIMENTAL
Intervention: Flour inhalation challenge
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control inhalation challenge
Number of subjects: 10
Study: 21186929

Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment combined with contingency management for up to 12 weeks
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Higher rates of delay discounting
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Age and income
Number of subjects: 152
Study: 18609150

Group type: EXPERIMENTAL
Intervention: Unkilned oats
Number of subjects: 32

Group type: COMPARATOR
Intervention: Kilned oats
Number of subjects: 32
Study: 15703367

Group type: EXPERIMENTAL
Intervention: 200 mg dexloxiglumide (3 times a day on days 17-20, followed by a single dose on day 21)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 24
Study: 11978685

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Biphasic human insulin 30 (BHI 30)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Biphasic insulin lispro 25 (Mix25)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 61
Study: 11907926

Group type: EXPERIMENTAL
Intervention: Various treatments for menopause (specific treatments not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cochrane Collaboration systematic reviews
Number of subjects: 0
Study: 7665807

Group type: EXPERIMENTAL
Intervention: Fluoxetine continuation therapy
Number of subjects: 41
Study: 2468920

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg b.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg b.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Xamoterol (200 mg b.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (digoxin alone)
Number of subjects: 0
Study: 792358

Group type: EXPERIMENTAL
Intervention: Amikacin (7.5 mg/kg twice daily)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Amikacin (150 or 200 mg every hr)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Gentamicin (60-80 mg every 8 hr)
Number of subjects: 113
Study: 31543954

Group type: EXPERIMENTAL
Intervention: Handwritten invitation letter
Number of subjects: 317

Group type: COMPARATOR
Intervention: Printed invitation letter
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 317
Study: 28471840

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 2558

Group type: EXPERIMENTAL
Intervention: Point-of-Care CD4 Count Testing (POC CD4)
Number of subjects: 2558

Group type: EXPERIMENTAL
Intervention: Care Facilitation (CF)
Number of subjects: 2558

Group type: EXPERIMENTAL
Intervention: Transport Reimbursement
Number of subjects: 2558
Study: 25829124

Group type: EXPERIMENTAL
Intervention: Baltimore Healthy Eating Zones intervention
Number of subjects: 242
Study: 24201232

Group type: EXPERIMENTAL
Intervention: Risperidone plus amantadine (100 mg/d for patients <30 kg or 150 mg/d for patients >30 kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Risperidone plus amantadine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Risperidone plus placebo
Number of subjects: 40
Study: 21529927

Group type: EXPERIMENTAL
Intervention: Stapler closure
Number of subjects: 450

Group type: COMPARATOR
Intervention: Hand-sewn closure
Number of subjects: 450
Study: 19892078

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (Seeking Safety; SS) plus treatment-as-usual (TAU)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) alone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (Seeking Safety; SS)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Both conditions (SS and TAU)
Number of subjects: 49
Study: 16924035

Group type: COMPARATOR
Intervention: Single PYGM mutation carriers
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Patients with McArdle disease
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 26
Study: 15253846

Group type: EXPERIMENTAL
Intervention: lavender oil
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: thyme oil
Number of subjects: 7

Group type: COMPARATOR
Intervention: unscented grapeseed oil
Number of subjects: 7
Study: 11475459

Group type: EXPERIMENTAL
Intervention: Total Contact Cast (TCC)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Customized Pneumatic Pre‐fabricated Walking Brace (PWB)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Running Shoe (RS)
Number of subjects: 9
Study: 9236587

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate for 14 days
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate for 28 days
Number of subjects: 360

Group type: COMPARATOR
Intervention: Penicillin V for 14 days
Number of subjects: 360

Group type: COMPARATOR
Intervention: Penicillin V for 28 days
Number of subjects: 360
Study: 8537919

Group type: EXPERIMENTAL
Intervention: Light-curing composite resin cement
Number of subjects: 25

Group type: COMPARATOR
Intervention: Dual-curing composite resin cement
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Inlays inserted in molars
Number of subjects: 25

Group type: COMPARATOR
Intervention: Inlays inserted in premolars
Number of subjects: 25
Study: 2677260

Group type: COMPARATOR
Intervention: 5‐fluorouracil (5‐FU), 600 mg/m2/week for 6 weeks (arm A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 5‐FU + folinic acid (FA), 200 mg/m2/week for 6 weeks (arm B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 5‐FU, 600 mg/m2/week for 6 weeks (arm A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 5‐FU + FA, 200 mg/m2/week for 6 weeks (arm B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 5‐FU + FA (arm B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 5‐FU (arm A)
Number of subjects: 80
Study: 367679

Group type: EXPERIMENTAL
Intervention: 10 fractions in 22 days
Number of subjects: 98

Group type: COMPARATOR
Intervention: 30 fractions in 42 days
Number of subjects: 98
Study: 31830535

Group type: EXPERIMENTAL
Intervention: Video game-based occupational therapy (VG)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional rehabilitation (CR)
Number of subjects: 51
Study: 31419257

Group type: EXPERIMENTAL
Intervention: Girls Active programme
Number of subjects: 997

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 997
Study: 27841946

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (BG: 100‐140 mg/dL)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Conservative glycemic control (BG: 141‐180 mg/dL)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 302

Group type: COMPARATOR
Intervention: Conservative glycemic control
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Intensive and Conservative glycemic control
Number of subjects: 302
Study: 24197754

Group type: EXPERIMENTAL
Intervention: Stochastic whole body vibration (WBV) applied for four days, five stimulus trains of 60 seconds at a frequency of 6.5 Hz with 60 seconds resting time between stimuli (n=17).
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham group received the same treatment with 1 Hz (n=15).
Number of subjects: 32
Study: 22454004

Group type: EXPERIMENTAL
Intervention: Flexible (MIB) regimen
Number of subjects: 1067

Group type: COMPARATOR
Intervention: Conventional 28-day regimen
Number of subjects: 1067

Group type: COMPARATOR
Intervention: Fixed extended regimen
Number of subjects: 1067
Study: 20012450

Group type: EXPERIMENTAL
Intervention: High-performing group (HP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-performing group (LP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Peak treadmill running velocity (PV), running economy (RE), lactate threshold (LT)
Number of subjects: 24